# Eliglustat prevents acute kidney injury caused by Shiga toxin 2 in lethal and sublethal rat models of hemolytic uremic syndrome

## TL;DR

Eliglustat prevents kidney damage caused by Shiga toxin 2 in rat models of hemolytic uremic syndrome, offering a potential treatment for acute kidney injury in humans.

## Contribution

This study demonstrates that eliglustat can prevent acute kidney injury caused by Shiga toxin 2 in both lethal and sublethal rat models.

## Key findings

- Eliglustat reduced Gb3 levels and prevented renal injury from both lethal and sublethal doses of Shiga toxin 2.
- Pretreatment with eliglustat prevented mortality in rats injected with the lethal dose of Shiga toxin 2.
- Eliglustat treatment did not cause renal or systemic side effects in the rats.

## Abstract

Shiga toxin-producing Escherichia coli is the main cause of post-diarrheal hemolytic uremic syndrome (HUS), which produces acute kidney injury mainly in children. Shiga toxin exerts its action by binding to the glycolipid globotriaosylceramide (Gb3) on the cell surface of target tissues. In humans, the kidneys are the organs most affected by Shiga toxin, where high Gb3 expression in glomerular endothelial and tubular epithelial cells leads to a combined glomerulopathy and tubulopathy that drives acute kidney injury. The aim of the present work was to evaluate the effectiveness of oral treatment with eliglustat (EG), an inhibitor of glucosylceramide synthase, the first step of glycosphingolipid biosynthesis, in preventing the effects of Shiga toxin 2 (Stx2) in lethal and sublethal models of HUS in rats.

Male juvenile Sprague–Dawley rats (∼100 g body weight (bw)) were intraperitoneally injected with lethal (5 ng/g bw) or sublethal (1 ng/g bw) doses of Stx2, or eluent. Some rats were orally treated with EG (15 mg/d or 25 mg/d) for 0–2 days, until 2 days or 3 days post-injection. Rat survival, renal Gb3 expression, renal function, histopathological observations, and aquaporin 1 (AQP1) and neutrophil gelatinase-associated lipocalin (NGAL) tubular expression were evaluated.

Rats injected with the Stx2 lethal dose showed significant kidney injury with extended tubular necrosis and some glomerular alterations at 3 days post-injection. The Stx2 sublethal dose caused significantly less renal injury extension than the lethal dose, showing only tubular damage. The expression of AQP1 and NGAL corroborated the tubular alteration in Stx2-injected rats. The oral treatment with EG reduced Gb3 renal levels and, therefore, significantly prevented the renal injury caused by lethal and sublethal doses of Stx2 in rats. Moreover, the pretreatment for 2 days with EG prevented the mortality in those rats injected with the Stx2 lethal dose. The EG treatment did not cause renal or systemic alterations. The effectiveness of EG treatment depended on the dose and the pretreatment time.

The oral treatment with EG could be a therapeutic strategy to prevent the action of Stx2 and the development of acute kidney injury in diarrhea-associated HUS patients.